NCT06981390View on ClinicalTrials.gov

Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 20, 2026

Study Completion Date

March 20, 2026

Conditions
Coronary Artery DiseaseCoronary Artery Bypass GraftingSaphenous VeinDual Antiplatelet Therapy
Interventions
DRUG

Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)

Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy

DRUG

Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)

Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy

DRUG

Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)

Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy

Trial Locations (1)

130000

RECRUITING

the Second Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Kexiang Liu, MD

OTHER